The Nishi-Shinjuku Illumination Market Lighting Ceremony, a New Illumination in Tokyo, Held to Illuminate the Nighttime in Nishi-Shinjuku!
11.12.2024 08:00:00 CET | Business Wire | Press release
The “TOKYO NIGHTTIME PROJECT” has been launched in the Nishi-Shinjuku area of Shinjuku-ku, Tokyo, with the aim of revitalizing night tourism. The project, by collaborating with organizations in the surrounding area, enlivens nighttime in Nishi-Shinjuku, an area where tradition and innovation intersect, with light displays and other activities to create a lively atmosphere for visitors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203634601/en/
The Illuminations (Photo: Business Wire)
"Nishi-Shinjuku Illumination Market” started on November 28, 2024. On Chuo-dori Avenue along the Tokyo Metropolitan Government Building, approximately 200,000 champagne gold LED lights illuminate the street for as long as 200 meters, creating a fantastic night scene, a new illumination spot in Tokyo.
At the lighting ceremony, Judoka Hifumi Abe and Uta Abe, both from the Park24 club, appeared as guests. They pressed the light button following the countdown, and the street was enveloped in glittering champagne gold lights.
TOKYO NIGHTTIME PROJECT Overview
- Sponsor: Tokyo Nighttime Project Executive Committee
- Co-sponsor: Tokyo Metropolitan Government
-
Programs:
Nishi-Shinjuku Illumination Market
New Year's Eve countdown event "Happy New Year Tokyo 2025" - Dates: Thursday, November 28th, 2024 to Monday/National holiday, January 13th, 2025
-
TOKYO NIGHTTIME PROJECT official website
https://tokyo-nighttime-project.jp/en/ -
Nishi-Shinjuku Illumination Market Overview
In addition to the illumination, food trucks and markets will line up, selling foods and goods that give a sense of Edo culture. For details, please visit the event website https://tokyo-nighttime-project.jp/en/market/ -
New Year’s Eve Countdown event “Happy New Year Tokyo 2025” Overview
"Happy New Year Tokyo 2025” will be held on New Year's Eve to close the year, a countdown event for many people including the Tokyo residents and foreign visitors, to experience the charms of Tokyo and share the anticipation for the New Year together.
With the theme of tradition and innovation, which are the attractions of Tokyo, there will be projection mapping, live performances by Japanese drummers and DJs, and talk shows by guests. In addition, new year wishes by the participants will be projected in the form of digital ema (votive picture tablet).
For details, please visit the event website https://tokyo-nighttime-project.jp/en/countdown/
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203634601/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom